Search research articles
Contact Us
Filters
Showing results (141-150 of 184) with videos related to
Page
of 19
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
February 28, 2018
PRRT genomic signature in blood for prediction of <sup>177</sup>Lu-octreotate efficacy
Lisa Bodei, Mark S Kidd, Aviral Singh, et al.
BMC Cancer
|
March 18, 2014
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study
Alfredo Berruti, Nicola Fazio, Anna Ferrero, et al.
Neuroendocrinology
|
August 29, 2018
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
Jaume Capdevila, Lisa Bodei, Philippa Davies, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 19, 2021
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
Silvia Nicolini, Lisa Bodei, Alberto Bongiovanni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 8, 2023
SNMMI Consensus Statement on Patient Selection and Appropriate Use of
Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, et al.
Radiology
|
April 18, 2023
A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes
Robert Seifert, Sazan Rasul, Konstantin E Seifert, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 14, 2017
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
Thorsten D Poeppel, Daria Handkiewicz-Junak, Michael Andreeff, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 27, 2022
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer
Joshua A Korsen, Julia A Gutierrez, Kathryn M Tully, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 7, 2025
Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy
Milan Grkovski, Simone S Krebs, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 23, 2020
γ-Tocotrienol-Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs
Sang-Gyu Lee, Teja Muralidhar Kalidindi, Hanzhi Lou, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 184) with videos related to
Sort By:
Page
of 19
European Journal of Nuclear Medicine and Molecular Imaging
|
February 28, 2018
PRRT genomic signature in blood for prediction of <sup>177</sup>Lu-octreotate efficacy
Lisa Bodei, Mark S Kidd, Aviral Singh, et al.
BMC Cancer
|
March 18, 2014
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study
Alfredo Berruti, Nicola Fazio, Anna Ferrero, et al.
Neuroendocrinology
|
August 29, 2018
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
Jaume Capdevila, Lisa Bodei, Philippa Davies, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 19, 2021
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
Silvia Nicolini, Lisa Bodei, Alberto Bongiovanni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 8, 2023
SNMMI Consensus Statement on Patient Selection and Appropriate Use of
Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, et al.
Radiology
|
April 18, 2023
A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes
Robert Seifert, Sazan Rasul, Konstantin E Seifert, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 14, 2017
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
Thorsten D Poeppel, Daria Handkiewicz-Junak, Michael Andreeff, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 27, 2022
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer
Joshua A Korsen, Julia A Gutierrez, Kathryn M Tully, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 7, 2025
Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy
Milan Grkovski, Simone S Krebs, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 23, 2020
γ-Tocotrienol-Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs
Sang-Gyu Lee, Teja Muralidhar Kalidindi, Hanzhi Lou, et al.
Page
of 19